Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial.

Neylan, Thomas C; Richards, Anne; Metzler, Thomas J.; Ruoff, Leslie M.; Varbel, Jonathan; O'Donovan, Aoife; Sivasubramanian, Melinda; Motraghi, Terri E; Hlavin, Jennifer; Batki, Steven L; Inslicht, Sabra S; Samuelson, Kristin W; Morairty, Stephen R.; Kilduff, Thomas S.

doi:10.1093/sleep/zsaa080

Record: found
Abstract: found
Article: not found

Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial.

Author(s): Thomas C Neylan ¹ ^, ² ^, ³ ^, ⁴ , Anne Richards ¹ ^, ² ^, ³ , Thomas J Metzler ¹ ^, ² ^, ³ , Leslie M Ruoff ¹ ^, ² ^, ³ , Jonathan Varbel ¹ ^, ² ^, ³ , Aoife O'Donovan ¹ ^, ² ^, ³ , Melinda Sivasubramanian ¹ ^, ² ^, ³ , Terri Motraghi ¹ ^, ² ^, ³ , Jennifer Hlavin ¹ ^, ² ^, ³ , Steven L Batki ¹ ^, ² ^, ³ , Sabra S Inslicht ¹ ^, ² ^, ³ , Kristin Samuelson ¹ ^, ² ^, ³ ^, ⁵ , Stephen R Morairty ⁶ , Thomas S Kilduff ⁶

Publication date (Electronic): October 13 2020

Journal: Sleep

Publisher: Oxford University Press (OUP)

Keywords: almorexant, cognitive dysfunction, humans, hypnotics and sedatives, psychomotor performance, zolpidem

Read this article at

ScienceOpenPublisher PMC

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Hypnotic medications can adversely affect behavior during unanticipated awakenings during the night. Animals treated with the hypocretin (Hcrt) receptor antagonist almorexant (ALM) have less acute cognitive impairment compared to the GABAA receptor modulator zolpidem (ZOL). This study aimed to determine whether ALM produces less acute cognitive impairment than ZOL in human subjects.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Sleep

Title: Sleep

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 1550-9109

ISSN (Print): 0161-8105

Publication date (Electronic): October 13 2020

Volume: 43

Issue: 10

Affiliations

[1 ] Department of Psychiatry, University of California San Francisco, San Francisco, CA.

[2 ] San Francisco Veterans Affairs Medical Center, San Francisco, CA.

[3 ] Sierra-Pacific Mental Illness Research Educational and Clinical Center, Department of Veterans Affairs, Palo Alto, CA.

[4 ] Department of Neurology, University of California San Francisco, San Francisco, CA.

[5 ] Department of Psychology, University of Colorado, Colorado Springs, CO.

[6 ] Center for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA.

Article

Publisher Item ID: 5821579

DOI: 10.1093/sleep/zsaa080

PMC ID: 7551303

PubMed ID: 32303763

SO-VID: 05f36546-5e34-4a10-88fc-4ff16524afea

History

Keywords: almorexant,cognitive dysfunction,humans,hypnotics and sedatives,zolpidem,psychomotor performance

Data availability:

Keywords: almorexant, cognitive dysfunction, humans, hypnotics and sedatives, zolpidem, psychomotor performance

Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial.

Read this article at

Abstract

Related collections

Horses and Humans Research Foundation

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 82

Cited by 9